- Home
- Automated
- List of product information
- PURINETONE TABLETS 50 MG [SIN10810P]
PURINETONE TABLETS 50 MG [SIN10810P]
Active ingredients: PURINETONE TABLETS 50 MG
Last updated 26 October 2025
On this page
Product Info
PURINETONE TABLETS 50 MG
[SIN10810P]
Product information
Active Ingredient and Strength | MERCAPTOPURINE - 50 MG |
Dosage Form | TABLET |
Manufacturer and Country | KOREA UNITED PHARMACEUTICAL INC - KOREA, REPUBLIC OF |
Registration Number | SIN10810P |
Licence Holder | SHOEI UNIVERSAL CORPORATION PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | L01BB02 |
INDICATIONS
Mercaptopurine is indicated for treatment or maintenance therapy in acute leukemia, acute lymphoblastic leukemia, and acute myelogenous leukemia.
Mercaptopurine is also used in the treatment of chronic granulocytic leukemia.
DOSAGE AND ADMINISTRATIONS
For adults and children the usual dose is 2.5 mg/kg bodyweight per day, but the dose and duration of administration depend on the nature and dosage of other cytotoxic agents given in conjunction with Mercaptopurine. The dosage should be carefully adjusted to suit the individual patient. Mercaptopurine has been used in various combination therapy schedules for acute leukemia and the literature should be consulted for details. Consideration should be given to reducing the dosage in patients with impaired hepatic or renal function. When allopurinol and mercaptopurine are administered concomitantly it is essential that only a quarter of the usual dose of mercaptopurine is given since allopurinol decreases the rate of catabolism of mercaptopurine.
CONTRAINDICATIONS
Purinetone should not be used in patients who have a hypersensitivity to mercaptopurine or any component of the formulation.
Purinetone contains lactose and should not be taken by patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.